Somaxon and CJ CheilJedang Announce Silenor(R) Collaboration in South Korea - MarketWatch (press release)
Somaxon and CJ CheilJedang Announce Silenor(R) Collaboration in South KoreaMarketWatch (press release)Silenor is a low-dose (3 mg and 6 mg) oral tablet formulation of doxepin, and is the first and only non-scheduled prescription sleep medication approved to treat insomnia characterized by difficulties with sleep maintenance.
Infinite itch: Learning to live with hives - Sarasota Herald-Tribune
Sarasota Herald-TribuneInfinite itch: Learning to live with hivesSarasota Herald-TribuneBut doxepin, the drug that finally suppressed the hives, made him so sleepy that he repeatedly dozed off on a desk during six weeks of job training.
Somaxon and CJ CheilJedang Announce Silenor® Collaboration in South Korea - SunHerald.com
SunHerald.
Somaxon, CJ CheilJedang sign Silenor commercialization agreement - Pharmaceutical Business Review
Somaxon, CJ CheilJedang sign Silenor commercialization agreementPharmaceutical Business ReviewSomaxon Pharmaceuticals and CJ CheilJedang have signed a commercialization agreement in South Korea for Silenor (doxepin) to treat insomnia.
Paladin Reports First Quarter 2012 Results Achieves Record Revenues - MarketWatch (press release)
Paladin Reports First Quarter 2012 Results Achieves Record RevenuesMarketWatch (press release)Silenor(R) is a low-dose oral tablet formulation of doxepin indicated for the treatment and symptomatic relief of insomnia.